Aim: To investigate the association between known inflammatory bowel disease (IBD)-associated genetic variants and development of paediatric IBD, and specific clinical sub-phenotypes. Material and methods: In this case-control study we included IBD patients b 18 years of age at diagnosis from the Danish National Patient Registry and healthy children b 18 years of age were randomly selected from the Danish Central Office of Civil Registration. The latter had filled out a questionnaire regarding health status, and DNA was obtained from blood samples and the buccal mucosa. Patient files were retrieved and clinical information was extracted. DNA was obtained from Guthrie cards from the Danish National Neonatal Screening Biobank (PKU-biobanken) at Statens Serum Institut and from blood samples. Results: A total of 588 IBD patients (244 Crohn's disease (CD), 318 ulcerative colitis (UC) and 26 IBD-unclassified (IBDU)) and 543 healthy controls were included. We found an association between CD and rs22411880 (ATG16L1, odds ratio (OR) = 1.7 [1.1-1.7], p = 0.003), rs5743289 (NOD2, OR = 1.4 [1.1-1.9], p = 0.009) and the paediatric specific rs1250550 (ZMIZ1, OR = 0.7 [0.5-0.9], p = 0.01). None of the investigated 41 SNPs were associated with disease localisation, medical treatment or surgery after correcting for multiple analyses. Conclusion: We found an association between CD and three previously published genetic variants and replicated the association with the paediatric specific ZMIZ1 gene. No Bonferroni corrected significant genotype-phenotype associations were found. For future studies aimed at
Introduction
Inflammatory bowel disease (IBD) includes Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis/IBD unclassified (IBDU). The aetiology of IBD is unknown, but it is thought to originate from a complex interplay between environmental-and genetic factors. 1 Over the past decade our understanding of the genetics of IBD has improved using genome wide associations studies (GWA studies). Several GWA studies in adult IBD patients have been published [2] [3] [4] [5] [6] and subsequent meta-analyses have identified 163 genetic loci associated with IBD. [7] [8] [9] [10] However, the loci discovered so far only cover around 25-30% of the genetic heritability to IBD. 8 To date two GWA studies have been conducted using paediatric IBD patients. 11, 12 In the study by Kugathasan et al., 12 two not previously published loci were identified: one on chromosome 20q13 (rs2315008 and rs4809330) and one on21q22 (rs2836878). Both loci were in non-coding regions; however the region on 20q13 was in linkage disequilibrium (LD) with a region harbouring the gene encoding TNFRSF6B (tumour necrosis factor receptor superfamily member 6b). Further analysis showed that TNFRSF6B mRNA expression was higher in colonic biopsies from IBD patients compared to healthy controls. No gene-containing regions were in LD with the locus on 21q22. The multicentre GWA study by Imielinski et al. 11 included patients from Italy, Scotland, the United States and Canada. A subset of these patients was also included in Ref. 12 In this study, five new regions were shown to be associated with early onset IBD: 16p11 (rs8049439) near the IL27 gene, 22q12 (rs2412973), 10q22 (rs1250550), 2q37 (rs4676410) and 19q13 (rs10500264). Subsequent meta-analysis of the paediatric cohorts confirmed 21 of the previously reported 32 susceptibility loci associated with adult CD. 11 In UC, 8 of the 17 susceptibility loci were also found in paediatric UC. 11 These results indicate a shared genetic susceptibility among adult-and paediatric IBD patients.
To our knowledge, only one subsequent study 13 has replicated the findings by Imielinski et al. 11 The relationship between genotype and phenotype is of special clinical interest as it may improve our understanding of disease pathways (for instance the association between NOD2 and ileal disease localisation in CD), and aid in predicting disease course and treatment response. 14 ). The aim of our study was to investigate if known genetic variants are associated with IBD in the Danish paediatric population; and if these variants are associated with specific sub-phenotypes.
Material and methods

Patients
In our case-control study we included IBD patients below 18 years of age at diagnosis. Patients treated in a hospital setting in Denmark are prospectively registered using the diagnostic codes from the WHO International Classification of Diseases, version 10 (ICD-10). They are registered in the electronic register of the local hospitals and in the National Patient Registry (NPR) using the Civil Registration Number (CPR-number). The CPR-number is a unique number given to each person at birth. We extracted data from the NPR using CPR-numbers and ICD-10 codes DK500-519 of all patients below 18 years of age in Eastern Denmark. Since 1982 all parents and their newborn children have been offered the opportunity to participate in the Danish national neonatal screening programme for congenital diseases and more than 90% of families have participated. All blood samples are kept on Guthrie cards and frozen to −20°C in a biobank at Statens Serum Institut in Denmark.
All files from patients registered in NPR and who had DNA in the neonatal screening biobank at Statens Serum Institut or had agreed to have blood samples taken were retrieved and reviewed by one investigator (CJ) . Clinical data at the last date of follow-up were recorded and included gender, date of diagnosis, height and weight at diagnosis, disease localization at diagnosis, disease behaviour at last follow-up (CD only) according to the Montreal classification, 43 perianal disease (yes/no), medical treatment (systemic steroids, azathioprine (AZA)/6-mercaptopurine (6MP), methotrexate (MTX), infliximab (IFX), adalimumab (ADA)) and date of surgery. Only bowel resections were included in the analysis.
Disease localization in CD and UC was classified according to the Paris classification 44 and for analysis subdivided into extensive and non-extensive diseases. In UC, extensive and non-extensive diseases included E3/E4 and E1/E2, respectively. In CD, extensive disease included L3 and all patients with upper GI disease (L4) and non-extensive disease included L2 and L1.
Controls
Controls were selected as part of another study. 45 In short, controls b 18 years of age were randomly selected from the Danish Central Person Registry from Eastern Denmark, Funen and Aarhus. Only controls without an ICD-10 diagnosis of DK500-519 in the National Patient Registry were selected. As part of another questionnaire study, controls filled out data regarding their health status and controls with gastrointestinal-or autoimmune diseases were excluded.
DNA extraction
The DNA in this study was extracted from EDTA-stabilized blood samples, from Guthrie-cards or from cotton-swabs from the oral cavity. DNA was purified from peripheral leukocytes using a QIAamp blood mini kit (Qiagen, Hilden, Germany).
SNP selection and genotyping
A total of 52 SNPs (in 25 genes) were selected based on the results from previously published genetic studies on adultand paediatric IBD patients 4, 6, 8, 11, 30, [46] [47] [48] [49] [50] [51] [52] [53] [54] and the final selected SNPs were a result of failure or no failure in the genetic assays. An overview of all included SNPs is shown in Supplementary Table 1. Two Sequenom® assays were designed with a total of 52 SNPs. Genotyping was performed using the iPLEX Mass Array system (Sequenom®), housed at the KU Leuven Genomics Core Facility.
Quality control
SNPs with a call rate b 90%, Hardy-Weinberg equilibrium (HWE) p-value b 0.001 in controls (Bonferroni corrected) and/or minor allele frequency b 3% were excluded. Of the original 52 SNPs, 11 were excluded after quality control resulting in 41 SNPs for analysis.
Statistical analysis
Genotype association analysis comparing IBD patients and controls was done using the genetic package in R (R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria). Odds ratios (OR), 95%CI and p-values reported are from the log-additive model. The association analysis between genotype and time to medical treatment and first bowel resection was done using Cox-regression analysis and hazard ratio (HR) and values with 95%CI are reported. Association between genotype and time to medical treatment is considered a marker of disease course as the most severely affected patients will receive IM/biological treatment earlier than patients with a mild disease course.
Z-scores for height and weight were calculated using the healthy Danish paediatric population as a reference 55, 56 and the associations between z-scores and genotype were analysed using the Kruskal-Wallis one-way analysis of variance. In the genotype-phenotype analysis the significance level was Bonferroni corrected and p ≤ 0.001 (0.05/ 41) was used.
Power calculation was done using the programme PS Power and Sample Size Calculations (http://www.mc.vanderbilt.edu/ prevmed/ps/index.htm) and Quanto (http://hydra.usc.edu/ gxe/).
Ethical considerations
The study was approved by the regional ethical committee in the Capital Region of Denmark and a written consent was obtained from all participants in the study,
Results
Patient characteristics
A total of 588 paediatric IBD patients (244 CD, 318 UC, 26 IBDU) and 543 healthy controls were included. Patients were followed up for a median of 4.7 years (IQR 3-7.0). Patient demographics are shown in Table 1 .
Genetic association analysis
Results from selected SNPs (p-value b 0.1 or top five associated SNPs) are shown in Table 2 (results for all SNPs are shown in Supplementary Table 1) . We found that the T-allele in rs2241880 (ATG16L1) and the T-allele in paediatric specific rs1250550 (ZMIZ1) were associated with a decreased risk of developing CD (OR 0.7 (0.6-0.9), p = 0.003 and OR 0.7 (0.6-0.9), p = 0.01, respectively) and the T-allele in rs5743289 (NOD2) was associated with an increased risk of CD (OR 1.4 (1.1-1.9), p = 0.009). None of the variants studied reached genome-wide significance levels in our cohort.
Subphenotypic analysis
Several nominally significant associations were found (Supplementary Tables 2a-2d ), but these did not withstand correction for multiple testing. No SNPs were significantly associated with ileal disease localization in CD patients (data not shown).
Selected nominally significant associations are presented below.
In all IBD patients, rs5752792 (XBP1) (CC genotype (OR 0. 
Discussion
In this study, we investigated the association between previously published SNPs and development of IBD in Danish children and studied the relationship with clinical sub-phenotypes in the same IBD cohort.
Our study has several strengths and limitations. The cohort used in our study is very well characterized and phenotyping was done by a single investigator (CJ). Furthermore, it contains a relatively large paediatric UC cohort from a single country. However, the total size of our cohort is relatively small compared to the cohorts used in the multinational GWA studies where the original SNP associations were discovered. Our power calculation showed an 80% power of detecting an odds ratio of 1.7 or above in our case-control analysis and in the genotypephenotype analysis we had an 80% power of detecting OR of 2.2 or above (disease localisation) both assuming a Bonferroni corrected p-value of 0.001. Therefore, our study was not designed to detect small differences and this could be the reason for our negative results. However, as the supplementary tables show there are several signals regarding genotype influence on medical treatment (i.e. disease course) and surgery.
We found a nominal association between CD and rs5743289 (NOD2), rs2241880 (ATG16L1) and we replicated the finding of the recently identified paediatric specific rs1250550 (ZMIZ1).
The weak association with NOD 2 found in our study could be due to a low carrier rate of NOD2 mutations in Scandinavian children or because we have used a different SNP in the NOD2 gene than other groups. A Swedish paediatric study 57 reported a carrier rate of NOD2 mutations (rs2066844, rs2066845, rs5743293) in CD patients of 8.6% compared to 29% in the United States 58 and 60% in Germany. 59 However, the carrier rate of the minor risk allele was 21% in our cohort which is comparable to a study in adult Danish CD patients. 60 However, different SNPs in NOD2 (rs2066844, rs2066845, rs5743293) were used in the adult study, why direct comparison is difficult.
In the Swedish study 57 no association with disease localization was shown which underlines the complex genetic contribution to disease phenotype. The genetic contribution to disease phenotype is probably different between populations (as shown by the inconsistency in the reported carrier rates for different genes from different countries) which could explain our negative finding in our genotype-phenotype analysis.
In our study, we replicated the finding of one of the three recently identified paediatric specific SNPs 11 and found a significant protective (T-allele) association with CD susceptibility and rs1250550 (ZMIZ1). This is in accordance with another paediatric study from Canada 13 that included 563 CD patients b 19 years of age. A total of 19 SNPs were investigated including the paediatric specific SNPs and an association was found with rs1250550 (ZMIZ1) (OR = 0.8 [0.7-1.0], p = 0.026) and rs8049439 (IL27) (OR = 1.2 [1.0-1.4] , p = 0.04). 13 Another paediatric study has examined whether known adult CD susceptibility loci were associated with paediatric onset CD. 61 The study included 384 CD patients b 20 years of age at diagnosis and investigated 34 SNPs. The study used a p-value of ≤0.03 as the significance cut-off level and by using the same cut-off level in our cohort some of our findings were similar to theirs. An association with ATG16L1 (rs2241880) (p = 0.01) was shown similar to our cohort (p = 0.003), but no association with TNFSF15 (rs6478108), CDKAL1 (rs6908425) or PTPN22 (rs2476601) was found in our study. In our study, we could not show any Bonferroni-significant genotype-phenotype relationships. This could be due to a relatively low number of patients if effects are modest (OR b 2.2), or that phenotypes constructed from clinical data (extensive vs. non-extensive or based upon the Paris classification) have no genetic basis/relevance. However, several studies have investigated genotype-phenotype associations and have found associations between NOD2 and ileal disease localization, and stricturing disease behaviour in adult 62 and paediatric 37 CD patients. ATG16L1 has been associated with ileal disease (with or without colon involvement) in Canadian children with CD. 15 In contrast, in the Scottish paediatric CD population no association with CD or disease phenotype was shown 16 and attributed to low incidence of pure ileal disease in their cohort. Other paediatric studies have shown an association between SNPs in the IRGM gene and ileal disease localization 63 and penetrating disease behaviour 64 and ileocolectomy 65 in adult CD patients. In Canadian CD patients ileal disease (with or without colon involvement) was associated with ZNF365 and STAT3. 66 In Australian children with CD colonic disease localization was associated with IL23R and colonic/ileocolonic localization was associated with IBD5 and SLC22A4 and SLC22A5. 28 Few paediatric studies have examined the association between genotype and medical treatment. Genetic variants in the TNF-alpha gene (−308A) have been associated with a lower frequency of surgery and increased frequency of resistance to systemic steroid treatment in paediatric Italian CD patients. 67 NOD2 variants have in some adult CD studies, been associated with a higher remission rate after anti-TNF treatment. 68 In other studies this association has not been shown. 69 A combined adult and paediatric CD (n = 92) study from Israel failed to find an association between NOD2 mutations and disease phenotype and treatment response in neither adult nor paediatric patients. 70 In light of the above inconsistencies regarding genotypephenotype associations it could be of value to include serological markers in the risk assessment. This has been done in a recent adult study on CD patients 71 where a high quartile sum score from several serological markers (anti-CBir1, anti-OmpC, anti-I2, ASCA-IgA, ASCA-IgG and pANCA) and carriage of NOD2 mutations was predictive of complicated disease course. Further paediatric studies including genotype, serological markers and phenotype are warranted.
In conclusion, we found a nominal significant association between CD and two SNPS (rs2241880 (ATG16L1), rs5743289 (NOD2)) found in adult and paediatric CD patients and we replicated the finding of an association with the paediatric specific SNP (rs1250550 (ZMIZ1)). No significant genotypephenotype associations were shown in our paediatric cohort.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.crohns.2013.12.010.
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